NCT02602327 is a Phase 1 clinical trial of Tas-102 in Colon Cancer, sponsored by University of California, San Francisco.

Who is sponsoring NCT02602327?

NCT02602327 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT02602327?

Interventions in NCT02602327: Tas-102, SIR-Sphere.

What condition does NCT02602327 study?

NCT02602327 studies Colon Cancer, Rectal Cancer, Liver Metastases.

Is NCT02602327 still recruiting?

NCT02602327 is currently completed. Last updated 1 August 2022.

Last reviewed 2022-08-01 · How we verify

NCT02602327

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Completed Phase 1 Last updated 1 August 2022

What this trial tests

Phase 1 trial testing Tas-102 in Colon Cancer in 21 participants. Completed in 31 August 2021.

Timeline

9 January 2017

Primary endpoint
20 May 2021

31 August 2021

Quick facts

Lead sponsor	University of California, San Francisco
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	9 January 2017
Primary completion	20 May 2021
Estimated completion	31 August 2021
Sites	1 location across United States

Drugs / interventions tested

Tas-102
SIR-Sphere — full drug profile →

Conditions studied

Colon Cancer — all drugs for Colon Cancer →
Rectal Cancer — all drugs for Rectal Cancer →
Liver Metastases — all drugs for Liver Metastases →

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Colon Cancer or Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I dose escalation study (3+3 design) with a dose expansion arm (12 patients) designed to evaluate safety of the combination of Tas-102 and radioembolization using Yttrium-90 (90Y) resin microspheres for patients with chemotherapy-refractory liver-dominant chemotherapy-refractory metastatic colorectal cancer (mCRC).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases.
Kennedy A, Cohn M, Coldwell DM, Drooz A, et al · · 2017 · cited 38× · PMID 28890810 · DOI 10.21037/jgo.2017.03.10
Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.
Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, et al · · 2017 · cited 32× · PMID 29299370 · DOI 10.21037/jgo.2017.09.10
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with <sup>90</sup>Y resin microspheres for chemo-refractory colorectal liver metastases.
Fidelman N, Atreya CE, Griffith M, Milloy MA, et al · · 2022 · cited 11× · PMID 36514060 · DOI 10.1186/s12885-022-10401-0
Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.
Hanna DL, Lenz HJ. · · 2016 · cited 8× · PMID 27031164 · DOI 10.1586/17512433.2016.1172961
Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil.
Puthiamadathil JM, Weinberg BA. · · 2017 · cited 7× · PMID 29056855 · DOI 10.2147/cmar.s113320

Verify or expand the search:

Other recruiting trials for Colon Cancer

Currently open trials in the same condition.

NCT06923787 — Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patient · Phase 2 · recruiting
NCT07279077 — Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advance · Phase 2 · recruiting
NCT07205965 — The Effect of Acceptance and Commitment Approach-Based Psychoeducation in Cancer Survivors · NA · active not recruiting
NCT07285356 — Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy · NA · recruiting
NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02602327 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 1 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02602327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing